{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:13:24Z","timestamp":1786979604987,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00066-025-02437-5","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T14:16:44Z","timestamp":1753366604000},"page":"1191-1207","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Is less more? Revisiting elective nodal irradiation in head and neck cancer"],"prefix":"10.1007","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7986-2169","authenticated-orcid":false,"given":"M.","family":"Haderlein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Frei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Weissmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. O.","family":"Gostian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. K.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fietkau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"issue":"1","key":"2437_CR1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.radonc.2013.10.010","volume":"110","author":"V Gregoire","year":"2014","unstructured":"Gregoire\u00a0V, Ang\u00a0K, Budach\u00a0W et\u00a0al (2014) Delineation of the neck node levels for head and neck tumors: a\u00a02013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol 110(1):172\u2013181. https:\/\/doi.org\/10.1016\/j.radonc.2013.10.010","journal-title":"Radiother Oncol"},{"key":"2437_CR2","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.oraloncology.2018.10.034","volume":"87","author":"V Gregoire","year":"2018","unstructured":"Gregoire\u00a0V, Grau\u00a0C, Lapeyre\u00a0M, Maingon\u00a0P (2018) Target volume selection and delineation (T\u00a0and\u00a0N)\u00a0for primary radiation treatment of oral cavity, oropharyngeal, hypopharyngeal and laryngeal squamous cell carcinoma. oral Oncol 87:131\u2013137. https:\/\/doi.org\/10.1016\/j.oraloncology.2018.10.034","journal-title":"oral Oncol"},{"issue":"11","key":"2437_CR3","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","volume":"31","author":"JP Machiels","year":"2020","unstructured":"Machiels\u00a0JP, Leemans\u00a0RC, Golusinski\u00a0W et\u00a0al (2020) Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(11):1462\u20131475. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.011","journal-title":"Ann Oncol"},{"key":"2437_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109958","author":"J Friborg","year":"2024","unstructured":"Friborg\u00a0J, Jensen\u00a0K, Eriksen\u00a0JG et\u00a0al (2024) Considerations for study design in the DAHANCA 35\u00a0trial of protons versus photons for head and neck cancer. Radiother Oncol. https:\/\/doi.org\/10.1016\/j.radonc.2023.109958 (109958)","journal-title":"Radiother Oncol"},{"key":"2437_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.radonc.2020.07.037","volume":"151","author":"K Jensen","year":"2020","unstructured":"Jensen\u00a0K, Friborg\u00a0J, Hansen\u00a0CR, et\u00a0al. The Danish Head and Neck Cancer Group (DAHANCA) 2020 radiotherapy guidelines. (2020) Radiother Oncol 151:149\u2013151. https:\/\/doi.org\/10.1016\/j.radonc.2020.07.037","journal-title":"Radiother Oncol"},{"issue":"1","key":"2437_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.radonc.2017.09.019","volume":"126","author":"CR Hansen","year":"2018","unstructured":"Hansen\u00a0CR, Johansen\u00a0J, Samsoe\u00a0E et\u00a0al (2018) Consequences of introducing geometric GTV to CTV margin expansion in DAHANCA contouring guidelines for head and neck radiotherapy. Radiother Oncol 126(1):43\u201347. https:\/\/doi.org\/10.1016\/j.radonc.2017.09.019","journal-title":"Radiother Oncol"},{"issue":"22","key":"2437_CR7","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1200\/JCO.2007.14.6647","volume":"26","author":"JA Langendijk","year":"2008","unstructured":"Langendijk\u00a0JA, Doornaert\u00a0P, Verdonck-de Leeuw\u00a0IM, Leemans\u00a0CR, Aaronson\u00a0NK, Slotman\u00a0BJ (2008) Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. j Clin Oncol 26(22):3770\u20133776. https:\/\/doi.org\/10.1200\/JCO.2007.14.6647 (Aug 1)","journal-title":"j Clin Oncol"},{"issue":"8","key":"2437_CR8","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.oraloncology.2011.05.012","volume":"47","author":"BL Ramaekers","year":"2011","unstructured":"Ramaekers\u00a0BL, Joore\u00a0MA, Grutters\u00a0JP et\u00a0al (2011) The impact of late treatment-toxicity on generic health-related quality of life in head and neck cancer patients after radiotherapy. oral Oncol 47(8):768\u2013774. https:\/\/doi.org\/10.1016\/j.oraloncology.2011.05.012","journal-title":"oral Oncol"},{"issue":"6","key":"2437_CR9","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00066-015-0824-4","volume":"191","author":"S Tribius","year":"2015","unstructured":"Tribius\u00a0S, Raguse\u00a0M, Voigt\u00a0C et\u00a0al (2015) Residual deficits in quality of life one year after intensity-modulated radiotherapy for patients with locally advanced head and neck cancer: Results of a\u00a0prospective study. Strahlenther Onkol 191(6):501\u2013510. https:\/\/doi.org\/10.1007\/s00066-015-0824-4","journal-title":"Strahlenther Onkol"},{"issue":"10","key":"2437_CR10","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00066-023-02124-3","volume":"199","author":"A Finger","year":"2023","unstructured":"Finger\u00a0A, Grohmann\u00a0M, Krause\u00a0L et\u00a0al (2023) Irradiation dose to the swallowing apparatus impacts nutritional status in head and neck cancer patients-results from the prospective randomized HEADNUT trial. Strahlenther Onkol 199(10):875\u2013880. https:\/\/doi.org\/10.1007\/s00066-023-02124-3","journal-title":"Strahlenther Onkol"},{"issue":"12","key":"2437_CR11","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00066-024-02296-6","volume":"200","author":"Y Tu","year":"2024","unstructured":"Tu\u00a0Y, Hao\u00a0L, Ding\u00a0Y, Zhong\u00a0Y, Hua\u00a0C, Jiang\u00a0L (2024) The influence of different radiotherapy doses on the mechanical properties and microstructure of the enamel and dentin of human premolar teeth. Strahlenther Onkol 200(12):1047\u20131056. https:\/\/doi.org\/10.1007\/s00066-024-02296-6","journal-title":"Strahlenther Onkol"},{"issue":"10","key":"2437_CR12","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1007\/s00066-024-02251-5","volume":"200","author":"PD Kovarik","year":"2024","unstructured":"Kovarik\u00a0PD, Cvek\u00a0J, Patil\u00a0R et\u00a0al (2024) Timing of development of osteoradionecrosis post head and neck radiotherapy: does a\u00a0safe time interval exist for dental extraction? Strahlenther Onkol 200(10):882\u2013894. https:\/\/doi.org\/10.1007\/s00066-024-02251-5","journal-title":"Strahlenther Onkol"},{"issue":"7","key":"2437_CR13","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1111\/odi.13599","volume":"27","author":"D Alterio","year":"2021","unstructured":"Alterio\u00a0D, Gugliandolo\u00a0SG, Augugliaro\u00a0M et\u00a0al (2021) IMRT versus 2D\/3D conformal RT in oropharyngeal cancer: A\u00a0review of the literature and meta-analysis. oral Dis 27(7):1644\u20131653. https:\/\/doi.org\/10.1111\/odi.13599","journal-title":"oral Dis"},{"issue":"1","key":"2437_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","volume":"363","author":"KK Ang","year":"2010","unstructured":"Ang\u00a0KK, Harris\u00a0J, Wheeler\u00a0R et\u00a0al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. n Engl J Med 363(1):24\u201335. https:\/\/doi.org\/10.1056\/NEJMoa0912217 (Jul 1)","journal-title":"n Engl J Med"},{"issue":"10166","key":"2437_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736","volume":"393","author":"H Mehanna","year":"2019","unstructured":"Mehanna\u00a0H, Robinson\u00a0M, Hartley\u00a0A et\u00a0al (2019) Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase\u00a03\u00a0trial. Lancet 393(10166):51\u201360. https:\/\/doi.org\/10.1016\/S0140-6736 (Jan 5)","journal-title":"Lancet"},{"issue":"4","key":"2437_CR16","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.ijrobp.2021.04.015","volume":"111","author":"D Rischin","year":"2021","unstructured":"Rischin\u00a0D, King\u00a0M, Kenny\u00a0L et\u00a0al (2021) Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01)\u2014A Trans-Tasman Radiation Oncology Group Study. int J Radiat Oncol Biol Phys 111(4):876\u2013886. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.04.015 (Nov 15)","journal-title":"int J Radiat Oncol Biol Phys"},{"issue":"10166","key":"2437_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736","volume":"393","author":"ML Gillison","year":"2019","unstructured":"Gillison\u00a0ML, Trotti\u00a0AM, Harris\u00a0J et\u00a0al (2019) Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a\u00a0randomised, multicentre, non-inferiority trial. Lancet 393(10166):40\u201350. https:\/\/doi.org\/10.1016\/S0140-6736 ((18)32779-X)","journal-title":"Lancet"},{"issue":"5","key":"2437_CR18","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.2016.68.3300","volume":"35","author":"S Marur","year":"2017","unstructured":"Marur\u00a0S, Li\u00a0S, Cmelak\u00a0AJ et\u00a0al (2017) E1308: Phase\u00a0II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. j Clin Oncol 35(5):490\u2013497. https:\/\/doi.org\/10.1200\/JCO.2016.68.3300 (Feb 10)","journal-title":"j Clin Oncol"},{"issue":"0","key":"2437_CR19","first-page":"41","volume":"602","author":"R Marshall","year":"2023","unstructured":"Marshall\u00a0R, Posner\u00a0JB, Takahashi\u00a0M, Roof\u00a0S, Genden\u00a0EM, Miles\u00a0B, Bakst\u00a0RL, Moshier\u00a0E, Vishal\u00a0G, Sonam\u00a0S, Krzystof\u00a0M (2023) The Quarterback trials: A\u00a0phase\u00a02 series of sequential studies of induction chemotherapy followed by reduced dose chemoradiation for human papillomavirus positive oropharynx cancer. J\u00a0Clin Oncol 602(0):41","journal-title":"J Clin Oncol"},{"issue":"2","key":"2437_CR20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1200\/JCO.21.01752","volume":"40","author":"RL Ferris","year":"2022","unstructured":"Ferris\u00a0RL, Flamand\u00a0Y, Weinstein\u00a0GS et\u00a0al (2022) Phase\u00a0II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). j Clin Oncol 40(2):138\u2013149. https:\/\/doi.org\/10.1200\/JCO.21.01752 (Jan 10)","journal-title":"j Clin Oncol"},{"issue":"suppl_7","key":"2437_CR21","first-page":"S808","volume":"33","author":"MJ ea","year":"2022","unstructured":"ea\u00a0MJ (2022) Phase\u00a03 KEYNOTE-412 study\u2014efficacy and safety of pembrolizumab + chemoradiation therapy in locally advanced head and neck squamous cell carcinoma. Ann Oncol 33(suppl_7):S808\u2013S869","journal-title":"Ann Oncol"},{"issue":"4","key":"2437_CR22","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045","volume":"22","author":"NY Lee","year":"2021","unstructured":"Lee\u00a0NY, Ferris\u00a0RL, Psyrri\u00a0A et\u00a0al (2021) Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a\u00a0randomised, double-blind, placebo-controlled, multicentre, phase\u00a03\u00a0trial. Lancet Oncol 22(4):450\u2013462. https:\/\/doi.org\/10.1016\/S1470-2045 ((20)30737-3)","journal-title":"Lancet Oncol"},{"issue":"6","key":"2437_CR23","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.canrad.2022.06.014","volume":"26","author":"Y El Houat","year":"2022","unstructured":"El Houat\u00a0Y, Bouvier\u00a0L, Baty\u00a0M et\u00a0al (2022) Head and neck cancers volume reduction: should we reduce our prophylactic node radiation to spare the antitumor immune response? cancer Radiother 26(6):916\u2013920. https:\/\/doi.org\/10.1016\/j.canrad.2022.06.014","journal-title":"cancer Radiother"},{"issue":"21","key":"2437_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/cancers13215269","volume":"13","author":"RI Chin","year":"2021","unstructured":"Chin\u00a0RI, Schiff\u00a0JP, Brenneman\u00a0RJ, Gay\u00a0HA, Thorstad\u00a0WL, Lin\u00a0AJ (2021) A\u00a0Rational Approach to Unilateral Neck RT for Head and Neck Cancers in the Era of Immunotherapy. Cancers (basel) 13(21):20. https:\/\/doi.org\/10.3390\/cancers13215269","journal-title":"Cancers (basel)"},{"issue":"1","key":"2437_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2214\/ajr.111.1.66","volume":"111","author":"DS Berger","year":"1971","unstructured":"Berger\u00a0DS, Fletcher\u00a0GH, Lindberg\u00a0RD, Jesse\u00a0RH Jr. (1971) Elective irradiation of the neck lymphatics for squamous cell carcinomas of the nasopharynx and oropharynx. Am J Roentgenol Radium Ther Nucl Med 111(1):66\u201372. https:\/\/doi.org\/10.2214\/ajr.111.1.66","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"2437_CR26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.radonc.2020.01.005","volume":"143","author":"S Deschuymer","year":"2020","unstructured":"Deschuymer\u00a0S, Nevens\u00a0D, Duprez\u00a0F et\u00a0al (2020) Randomized clinical trial on reduction of radiotherapy dose to the elective neck in head and neck squamous cell carcinoma; update of the long-term tumor outcome. Radiother Oncol 143:24\u201329. https:\/\/doi.org\/10.1016\/j.radonc.2020.01.005","journal-title":"Radiother Oncol"},{"issue":"1","key":"2437_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11136-020-02628-w","volume":"30","author":"S Deschuymer","year":"2021","unstructured":"Deschuymer\u00a0S, Nevens\u00a0D, Duprez\u00a0F et\u00a0al (2021) Randomized Clinical Trial on Reduction of Radiotherapy Dose to the Elective Neck in Head and Neck Squamous Cell Carcinoma: Results on the Quality of Life. Qual Life Res 30(1):117\u2013127. https:\/\/doi.org\/10.1007\/s11136-020-02628-w","journal-title":"Qual Life Res"},{"key":"2437_CR28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02194","author":"S van den Bosch","year":"2025","unstructured":"van den Bosch\u00a0S, Doornaert\u00a0PAH, Hoebers\u00a0FJP et\u00a0al (2025) Clinical Benefit and Safety of Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma: The UPGRADE-RT Multicenter Randomized Controlled Trial. j Clin Oncol. https:\/\/doi.org\/10.1200\/JCO-24-02194 (JCO2402194)","journal-title":"j Clin Oncol"},{"issue":"5","key":"2437_CR29","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.ijrobp.2017.12.277","volume":"100","author":"PD Maguire","year":"2018","unstructured":"Maguire\u00a0PD, Neal\u00a0CR, Hardy\u00a0SM, Schreiber\u00a0AM (2018) Single-Arm Phase\u00a02 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck. int J Radiat Oncol Biol Phys 100(5):1210\u20131216. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.12.277","journal-title":"int J Radiat Oncol Biol Phys"},{"issue":"22","key":"2437_CR30","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1200\/JCO.19.00463","volume":"37","author":"DJ Ma","year":"2019","unstructured":"Ma\u00a0DJ, Price\u00a0KA, Moore\u00a0EJ et\u00a0al (2019) Phase\u00a0II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma. j Clin Oncol 37(22):1909\u20131918. https:\/\/doi.org\/10.1200\/JCO.19.00463","journal-title":"j Clin Oncol"},{"issue":"5","key":"2437_CR31","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.ijrobp.2021.09.012","volume":"111","author":"DM Ma","year":"2021","unstructured":"Ma\u00a0DM, Price\u00a0K, Moore\u00a0EJ et\u00a0al (2021) MC1675, a\u00a0Phase\u00a0III Evaluation of De-Escalated Adjuvant Radiation Therapy (DART) vs. Standard Adjuvant Treatment for Human Papillomavirus Associated Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys 111(5):1324. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.09.012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2437_CR32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2967\/jnmt.120.249540","volume":"49","author":"S Lopes","year":"2021","unstructured":"Lopes\u00a0S, Ferreira\u00a0S, Caetano\u00a0M (2021) PET\/CT in the Evaluation of Hypoxia for Radiotherapy Planning in Head and Neck Tumors: Systematic Literature Review. J\u00a0Nucl Med Technol 49(2):107\u2013113. https:\/\/doi.org\/10.2967\/jnmt.120.249540","journal-title":"J Nucl Med Technol"},{"issue":"8","key":"2437_CR33","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1200\/JCO.23.01308","volume":"42","author":"NY Lee","year":"2024","unstructured":"Lee\u00a0NY, Sherman\u00a0EJ, Schoder\u00a0H et\u00a0al (2024) Hypoxia-Directed Treatment of Human Papillomavirus-Related Oropharyngeal Carcinoma. j Clin Oncol 42(8):940\u2013950. https:\/\/doi.org\/10.1200\/JCO.23.01308","journal-title":"j Clin Oncol"},{"issue":"16_suppl","key":"2437_CR34","doi-asserted-by":"publisher","first-page":"6007","DOI":"10.1200\/JCO.2024.42.16_suppl.6007","volume":"42","author":"NY Lee","year":"2024","unstructured":"Lee\u00a0NY, Sherman\u00a0EJ, Sch\u00f6der\u00a0H et\u00a0al (2024) Intra-treatment hypoxia directed major radiation de-escalation as definitive treatment for human papillomavirus-related oropharyngeal cancer. JCO 42(16_suppl):6007\u20136007. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.6007","journal-title":"JCO"},{"issue":"9","key":"2437_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1001\/jamanetworkopen.2024.36407","volume":"7","author":"C Gui","year":"2024","unstructured":"Gui\u00a0C, Wray\u00a0R, Schoder\u00a0H et\u00a0al (2024) Tumor Hypoxia on 18F-fluoromisonidazole Positron Emission Tomography and Distant Metastasis From Head and Neck Squamous Cell Carcinoma. Jama Netw Open 7(9):3. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.36407 (e2436407)","journal-title":"Jama Netw Open"},{"key":"2437_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030538","author":"M Haderlein","year":"2020","unstructured":"Haderlein\u00a0M, Speer\u00a0S, Ott\u00a0O et\u00a0al (2020) Dose Reduction to the Swallowing Apparatus and the Salivary Glands by De-Intensification of Postoperative Radiotherapy in Patients with Head and Neck Cancer: First (Treatment Planning) Results of the Prospective Multicenter DIREKHT Trial. Cancers (basel). https:\/\/doi.org\/10.3390\/cancers12030538","journal-title":"Cancers (basel)"},{"issue":"28","key":"2437_CR37","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1200\/JCO.19.00186","volume":"37","author":"JA Contreras","year":"2019","unstructured":"Contreras\u00a0JA, Spencer\u00a0C, DeWees\u00a0T et\u00a0al (2019) Eliminating Postoperative Radiation to the Pathologically Node-Negative Neck: Long-Term Results of a\u00a0Prospective Phase\u00a0II Study. j Clin Oncol 37(28):2548\u20132555. https:\/\/doi.org\/10.1200\/JCO.19.00186","journal-title":"j Clin Oncol"},{"key":"2437_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1447123","author":"M Haderlein","year":"2024","unstructured":"Haderlein\u00a0M, von der Grun\u00a0J et\u00a0al (2024) De-intensification of postoperative radiotherapy in head and neck cancer irrespective of human papillomavirus status-results of a\u00a0prospective multicenter phase\u00a0II trial (DIREKHT Trial). Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2024.1447123 (1447123)","journal-title":"Front Oncol"},{"issue":"4","key":"2437_CR39","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ijrobp.2020.03.021","volume":"107","author":"E Longton","year":"2020","unstructured":"Longton\u00a0E, Lawson\u00a0G, Bihin\u00a0B et\u00a0al (2020) Individualized Prophylactic Neck Irradiation in Patients with cN0 Head and Neck Cancer Based on Sentinel Lymph Node(s) Identification: Definitive Results of a\u00a0Prospective Phase\u00a01\u20132\u00a0Study. int J Radiat Oncol Biol Phys 107(4):652\u2013661. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.03.021","journal-title":"int J Radiat Oncol Biol Phys"},{"key":"2437_CR40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.radonc.2020.03.012","volume":"147","author":"PD de Veij Mestdagh","year":"2020","unstructured":"de Veij Mestdagh\u00a0PD, Walraven\u00a0I, Vogel\u00a0WV et\u00a0al (2020) SPECT\/CT-guided elective nodal irradiation for head and neck cancer is oncologically safe and less toxic: A\u00a0potentially practice-changing approach. Radiother Oncol 147:56\u201363. https:\/\/doi.org\/10.1016\/j.radonc.2020.03.012","journal-title":"Radiother Oncol"},{"issue":"5","key":"2437_CR41","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.ijrobp.2024.01.032","volume":"118","author":"JK Molitoris","year":"2024","unstructured":"Molitoris\u00a0JK, Witek\u00a0ME, Ferris\u00a0MJ et\u00a0al (2024) Early Outcomes for A Single-Arm Phase\u00a0I\/II Trial of Selective Avoidance of Nodal VolumEs at Minimal Risk (SAVER) in the Contralateral N0 Neck of Patients with p16-Positive Oropharynx Cancer. Int J Radiat Oncol Biol Phys 118(5):e11\u2013e12. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.01.032","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2437_CR42","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.ijrobp.2020.09.063","volume":"109","author":"DJ Sher","year":"2021","unstructured":"Sher\u00a0DJ, Pham\u00a0NL, Shah\u00a0JL et\u00a0al (2021) Prospective Phase\u00a02\u00a0Study of Radiation Therapy Dose and Volume De-escalation for Elective Neck Treatment of Oropharyngeal and Laryngeal Cancer. int J Radiat Oncol Biol Phys 109(4):932\u2013940. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.09.063","journal-title":"int J Radiat Oncol Biol Phys"},{"key":"2437_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz171","author":"TY Seiwert","year":"2019","unstructured":"Seiwert\u00a0TY, Foster\u00a0CC, Blair\u00a0EA et\u00a0al (2019) OPTIMA: a\u00a0phase\u00a0II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdz171","journal-title":"Ann Oncol"},{"issue":"5","key":"2437_CR44","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/annonc\/mdw051","volume":"27","author":"VM Villaflor","year":"2016","unstructured":"Villaflor\u00a0VM, Melotek\u00a0JM, Karrison\u00a0TG et\u00a0al (2016) Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. Ann Oncol 27(5):908\u2013913. https:\/\/doi.org\/10.1093\/annonc\/mdw051","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"2437_CR45","doi-asserted-by":"publisher","first-page":"6007","DOI":"10.1200\/JCO.2023.41.16_suppl.6007","volume":"41","author":"A Rosenberg","year":"2023","unstructured":"Rosenberg\u00a0A, Juloori\u00a0A, Agrawal\u00a0N et\u00a0al (2023) Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial. JCO 41(16_suppl):6007\u20136007. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.6007","journal-title":"JCO"},{"issue":"17","key":"2437_CR46","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1158\/1078-0432.CCR-23-0334","volume":"29","author":"DJ Sher","year":"2023","unstructured":"Sher\u00a0DJ, Moon\u00a0DH, Vo\u00a0D, et\u00a0al. Efficacy and Quality-of-Life Following Involved Nodal Radiotherapy for Head and Neck Squamous Cell Carcinoma: The INRT-AIR Phase II Clinical Trial (2023) Clin Cancer Res 29(17):3284\u20133291. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0334","journal-title":"Clin Cancer Res"},{"key":"2437_CR47","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.annonc.2024.08.913","volume":"35","author":"J Castelli","year":"2024","unstructured":"Castelli\u00a0J, Sun\u00a0X, Neveu\u00a0E et\u00a0al (2024) 852MO REWRITE–GORTEC 2018\u201302: Radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck. Ann Oncol 35:615. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.913","journal-title":"Ann Oncol"},{"issue":"2, Supplement","key":"2437_CR48","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.ijrobp.2024.08.022","volume":"120","author":"SV Bratman","year":"2024","unstructured":"Bratman\u00a0SV, Karam\u00a0I, Waldron\u00a0JN et\u00a0al (2024) A\u00a0Phase\u00a0II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol 120(2, Supplement):S7\u2013S8. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.08.022","journal-title":"Int J Radiat Oncol"},{"issue":"5","key":"2437_CR49","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1016\/j.ijrobp.2024.01.063","volume":"118","author":"GB Biedermann","year":"2024","unstructured":"Biedermann\u00a0GB, Dooley\u00a0L, Overschmidt\u00a0J (2024) ENID: Phase\u00a0II Trial of Definitive Chemoradiation with Elective Nodal Irradiation Dose De-Escalation for P16 Positive Squamous Cell Carcinoma of the Oropharynx. Int J Radiat Oncol 118(5):e27. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.01.063","journal-title":"Int J Radiat Oncol"},{"key":"2437_CR50","doi-asserted-by":"publisher","first-page":"100696","DOI":"10.1016\/j.ctro.2023.100696","volume":"44","author":"S van den Bosch","year":"2024","unstructured":"van den Bosch\u00a0S, Takes\u00a0RP, de Ridder\u00a0M et\u00a0al (2024) Personalized neck irradiation guided by sentinel lymph node biopsy in patients with squamous cell carcinoma of the oropharynx, larynx or hypopharynx with a\u00a0clinically negative neck: (Chemo)radiotherapy to the PRIMary tumor only. Protocol of the PRIMO study. Clin Transl Radiat Oncol 44:100696. https:\/\/doi.org\/10.1016\/j.ctro.2023.100696","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1","key":"2437_CR51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0360-3016","volume":"26","author":"LJ Peters","year":"1993","unstructured":"Peters\u00a0LJ, Goepfert\u00a0H, Ang\u00a0KK et\u00a0al (1993) Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a\u00a0prospective randomized trial. int J Radiat Oncol Biol Phys 26(1):3\u201311. https:\/\/doi.org\/10.1016\/0360-3016 ((93)90167-t)","journal-title":"int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2437_CR52","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.ijrobp.2024.08.014","volume":"120","author":"SS Yom","year":"2024","unstructured":"Yom\u00a0SS, Harris\u00a0J, Caudell\u00a0JJ et\u00a0al (2024) Interim Futility Results of NRG-HN005, A\u00a0Randomized, Phase\u00a0II\/III Non-Inferiority Trial for Non-Smoking p16+ Oropharyngeal Cancer Patients. Int J Radiat Oncol Biol Phys 120(2):S2\u2013S3. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.08.014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2437_CR53","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.1200\/JCO.2025.43.16_suppl.6012","volume":"43","author":"D Adkins","year":"2025","unstructured":"Adkins\u00a0D et\u00a0al (2025) Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Exploratory efficacy analyses of the phase\u00a03 KEYNOTE-689 study. JCO 43:6012\u20136012","journal-title":"JCO"},{"key":"2437_CR54","doi-asserted-by":"crossref","unstructured":"Bourhis J et\u00a0al (2025) NIVOPOSTOP (GORTEC 2018\u201301): A\u00a0phase\u00a0III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse. JCO 43: (LBA2-LBA2)","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA2"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02437-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-025-02437-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02437-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:41:38Z","timestamp":1761154898000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-025-02437-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":54,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2437"],"URL":"https:\/\/doi.org\/10.1007\/s00066-025-02437-5","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"27 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Haderlein, C.\u00a0Frei, T.\u00a0Weissmann, M.\u00a0Weber, R.\u00a0Lutz, A.O.\u00a0Gostian, S.K.\u00a0M\u00fcller, B.\u00a0Frey, and R.\u00a0Fietkau declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}